Esperion Expects Phase IIb Data By Year-End On Cholesterol Candidate
This article was originally published in The Pink Sheet Daily
The recently public company completed Phase IIa studies for lead candidate ETC-1002 and intends to complete a pair of Phase IIb studies before year-end.
You may also be interested in...
Company says FDA confirmed that cardiovascular outcomes data will not be required for initial submission of ETC-1002 in patients with familial hypercholesterolemia and atherosclerotic CV disease; Esperion expects to start Phase III development by the end of 2015.
Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.
Pfizer retains undisclosed stake in Esperion, which will focus on small-molecule dyslipidemia candidate.